The European Medicines Agency (EMA) on Monday, October 25 approved the administration of a third dose of the anti-Covid vaccine from the Moderna laboratory to people aged 18 and over, as health authorities worried about a lower level of protection after the first injections.
→ EXPLANATION. Third dose: what the Haute Autorité de santé recommends
Spikevax, the name of Moderna’s serum, is the second vaccine booster to receive the green light after Pfizer / BioNTech’s vaccine earlier this month. “The data showed that a third dose of Spikevax given six to eight months after the second dose resulted in increased antibody levels in adults with decreased antibody levels’the EMA said in a statement.
“Careful monitoring” for side effects
The health authorities of the 27 members of the European Union “May issue official recommendations on the use of booster doses, taking into account the local epidemiological situation”, added the Amsterdam-based watchdog. The agency says current data shows a pattern of side effects similar to that after the second dose.
→ EXPLANATIONS. Third dose: “Do I need a booster if I had the Covid after being vaccinated”?
“The risk of inflammatory heart problems and other very rare side effects after a booster is carefully monitored”, continues the EMA. “The booster dose is half the dose used after the first injections”, adds the agency.
Earlier this month, the agency approved booster shots of the Comirnaty (Pfizer / BioNTech) vaccine for those over 18, as well as additional doses of the Pfizer / BioNTech and Moderna remedies for people whose system immune system is severely weakened.